Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region

Clinical Drug Investigation

Volumn 34, Issue 9, 2014, Pages 673-679

  Nosek, Leszek ^a   Coester, Hans Veit ^a   Roepstorff, Carsten ^b   Thomsen, Henrik F ^b   Kristensen, Niels R ^b   Haahr, Hanne ^b   Heise, Tim ^a  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ABDOMINAL WALL MUSCULATURE; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTOID MUSCLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; STEADY STATE; THIGH; BIOLOGICAL MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84906939391     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0218-x     Document Type: Article

References (23)

1. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003;327:383-4.
2. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14(12):1081-7. doi:10.1111/j.1463-1326.2012.01636.x.
3. Minze MG, Dalal K, Irons BK. Removing barriers to insulin use. J Fam Pract. 2011;60:577-80.
4. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92:59-61.
5. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4:366-76.
6. Henriksen JE, Djurhuus MS, Vaag A, Thye-Ronn P, Knudsen D, Hother-Nielsen O, Beck-Nielsen H. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia. 1993;36:752-8.
7. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16:1592-7.
8. Süsstrunk H, Morell B, Ziegler WH, Froesch ER. Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels. Diabetologia. 1982;22:171-4.
9. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15:1484-93.
10. Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827-35.
11. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104-14.
12. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther. 2011;13(suppl 1):S5-14.
13. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13:677-84.
14. Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C, Potgieter MA, Lang AM, Koose T, Bernhardt E. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin. 2003;19:34-40.
15. Markussen J, Hougaard P, Ribel U, Sørensen AR, Sørensen E. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng. 1987;1:205-13.
16. Kurtzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54:S426.
17. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-64.
18. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: twofold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia. 2011;54:S425.
19. Henriksen JE, Vaag A, Hansen IR, Lauritzen M, Djurhuus MS, Beck-Nielsen H. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Diabet Med. 1991;8:453-7.
20. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813-9.
21. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-50.
22. Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. European Medicines Agency. 2010. http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 01/WC500070039.pdf. Accessed Apr 2014.
23. US Food and Drug Administration. Bioavailability and bioequivalence requirements. 21 CFR 21 Part 320. 2009. http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=320. Accessed Apr 2014.